Based on the information available, there is limited data on the specific interaction between lurbinectedin and anticoagulants. Lurbinectedin is a novel antineoplastic agent, primarily used for the treatment of platinum-sensitive relapsed ovarian cancer [1]. Anticoagulants, on the other hand, are medications that prevent blood clots.

In general, the concurrent use of antineoplastic agents and anticoagulants can increase the risk of bleeding due to the combined effects of these medications on the blood clotting process [2]. However, the extent of this risk can vary depending on the specific antineoplastic agent and anticoagulant being used.

In the case of lurbinectedin, there are currently no specific warnings or contraindications regarding its use with anticoagulants in the drug label [1]. This suggests that the manufacturer has not identified any significant interactions between these two classes of medications. However, this does not necessarily mean that there are no increased bleeding risks, as the available data may be limited.

Therefore, it is important for healthcare providers to carefully consider the potential risks and benefits of using lurbinectedin and anticoagulants together [2]. This may involve monitoring patients more closely for signs of bleeding, adjusting the dosage of the anticoagulant, or using alternative medications if necessary.

In summary, while there is limited data on the specific interaction between lurbinectedin and anticoagulants, the concurrent use of these medications can potentially increase the risk of bleeding. Healthcare providers should exercise caution when prescribing these medications together and monitor patients closely for signs of bleeding.

Sources:
[1] DrugPatentWatch.com. Lurbinectedin. https://www.drugpatentwatch.com/drugs/lurbinectedin
[2] Verso, M., & Agnelli, G. (2018). Management of antithrombotic therapy in patients with cancer. Thrombosis research, 162, 96-103. https://doi.org/10.1016/j.thromres.2018.01.013